ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Nikkei PMI

Pharmaceuticals and Biotechnology tops growth rankings in October Asia sector PMI

TOKYO -- Pharmaceuticals and biotechnology topped the list of output growth across 19 sectors in Asia this October with a sharp expansion that hit an eight-month high.

The Nikkei Asia Sector Purchasing Managers' Index, or PMI, showed that 16 out of the 19 monitored sectors registered expansion in October. Pharmaceuticals and biotechnology registered the highest rate of growth at 56.1, up from 51.1 in September, followed by forestry and paper products. Software and services, as well as insurance also showed strong output growth.

Readings above 50 signal expansion, while those below 50 indicate contraction.

Meanwhile healthcare services registered a sharp drop from the previous month`s 47.5 to 43.2, along with construction materials and automobiles & parts.

(Nikkei)

For more information, visit here.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 19th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media